B-Cell Non-Hodgkin Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major B-cell non-Hodgkin lymphoma markets are expected to exhibit a CAGR of 5.83% during 2024-2034.
The B-cell non-Hodgkin lymphoma market has been comprehensively analyzed in IMARC's new report titled "B-Cell Non-Hodgkin Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". B-cell non-Hodgkin lymphoma (NHL) refers to a type of cancer that originates from B cells, a category of white blood cells involved in the immune system's defense against infections. The symptoms of the ailment can vary depending on the specific subtype, stage of the disease, and organs or tissues affected. Some of the common indications are painless swelling of lymph nodes in the armpits, neck, or groin, unexplained weight loss, persistent fatigue, night sweats, fever, itching, etc. Various other possible symptoms may include abdominal pain or swelling, chest pain, difficulty breathing, bone pain, etc. The diagnosis of B-cell non-Hodgkin lymphoma involves a combination of clinical evaluation, imaging tests, and laboratory investigations. A healthcare professional will review the patient's medical history and conduct a physical exam to assess lymph nodes and organs. A biopsy of an affected lymph node or other involved tissues is usually performed to confirm the diagnosis and determine the specific subtype of B-cell NHL. Numerous additional tests, including blood work, immunophenotyping, molecular testing, etc., may be conducted to provide further information about the disease's characteristics.
The increasing cases of translocations, deletions, and mutations in specific genes that can disrupt the normal functioning of the B cells are primarily driving the B-cell non-Hodgkin lymphoma market. In addition to this, the rising prevalence of several associated risk factors, such as certain autoimmune conditions like rheumatoid arthritis and Sjцgren's syndrome, exposure to ionizing radiation, viral infections, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, including ibrutinib and idelalisib, which interfere with signaling pathways or cellular processes essential for cancer cell survival, thereby leading to tumor regression, is further bolstering the market growth. Apart from this, the inflating application of chimeric antigen receptor T-cell (CAR-T) therapy, which involves modifying a patient's own T-cells to express a receptor that recognizes and attacks cancer cells expressing particular antigens, like CD19, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of novel immune checkpoint inhibitors, enabling the immune system to better recognize and attack lymphoma cells, is expected to drive the B-cell non-Hodgkin lymphoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the B-cell non-Hodgkin lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for B-cell non-Hodgkin lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the B-cell non-Hodgkin lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the B-cell non-Hodgkin lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the B-cell non-Hodgkin lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current B-cell non-Hodgkin lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the B-cell non-Hodgkin lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the B-cell non-Hodgkin lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the B-cell non-Hodgkin lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of B-cell non-Hodgkin lymphoma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of B-cell non-Hodgkin lymphoma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of B-cell non-Hodgkin lymphoma by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with B-cell non-Hodgkin lymphoma across the seven major markets?
What is the size of the B-cell non-Hodgkin lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of B-cell non-Hodgkin lymphoma?
What will be the growth rate of patients across the seven major markets?
B-Cell Non-Hodgkin Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for B-cell non-Hodgkin lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the B-cell non-Hodgkin lymphoma market?
What are the key regulatory events related to the B-cell non-Hodgkin lymphoma market?
What is the structure of clinical trial landscape by status related to the B-cell non-Hodgkin lymphoma market?
What is the structure of clinical trial landscape by phase related to the B-cell non-Hodgkin lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the B-cell non-Hodgkin lymphoma market?
The B-cell non-Hodgkin lymphoma market has been comprehensively analyzed in IMARC's new report titled "B-Cell Non-Hodgkin Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". B-cell non-Hodgkin lymphoma (NHL) refers to a type of cancer that originates from B cells, a category of white blood cells involved in the immune system's defense against infections. The symptoms of the ailment can vary depending on the specific subtype, stage of the disease, and organs or tissues affected. Some of the common indications are painless swelling of lymph nodes in the armpits, neck, or groin, unexplained weight loss, persistent fatigue, night sweats, fever, itching, etc. Various other possible symptoms may include abdominal pain or swelling, chest pain, difficulty breathing, bone pain, etc. The diagnosis of B-cell non-Hodgkin lymphoma involves a combination of clinical evaluation, imaging tests, and laboratory investigations. A healthcare professional will review the patient's medical history and conduct a physical exam to assess lymph nodes and organs. A biopsy of an affected lymph node or other involved tissues is usually performed to confirm the diagnosis and determine the specific subtype of B-cell NHL. Numerous additional tests, including blood work, immunophenotyping, molecular testing, etc., may be conducted to provide further information about the disease's characteristics.
The increasing cases of translocations, deletions, and mutations in specific genes that can disrupt the normal functioning of the B cells are primarily driving the B-cell non-Hodgkin lymphoma market. In addition to this, the rising prevalence of several associated risk factors, such as certain autoimmune conditions like rheumatoid arthritis and Sjцgren's syndrome, exposure to ionizing radiation, viral infections, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, including ibrutinib and idelalisib, which interfere with signaling pathways or cellular processes essential for cancer cell survival, thereby leading to tumor regression, is further bolstering the market growth. Apart from this, the inflating application of chimeric antigen receptor T-cell (CAR-T) therapy, which involves modifying a patient's own T-cells to express a receptor that recognizes and attacks cancer cells expressing particular antigens, like CD19, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of novel immune checkpoint inhibitors, enabling the immune system to better recognize and attack lymphoma cells, is expected to drive the B-cell non-Hodgkin lymphoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the B-cell non-Hodgkin lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for B-cell non-Hodgkin lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the B-cell non-Hodgkin lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the B-cell non-Hodgkin lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the B-cell non-Hodgkin lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current B-cell non-Hodgkin lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the B-cell non-Hodgkin lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the B-cell non-Hodgkin lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the B-cell non-Hodgkin lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of B-cell non-Hodgkin lymphoma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of B-cell non-Hodgkin lymphoma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of B-cell non-Hodgkin lymphoma by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with B-cell non-Hodgkin lymphoma across the seven major markets?
What is the size of the B-cell non-Hodgkin lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of B-cell non-Hodgkin lymphoma?
What will be the growth rate of patients across the seven major markets?
B-Cell Non-Hodgkin Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for B-cell non-Hodgkin lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the B-cell non-Hodgkin lymphoma market?
What are the key regulatory events related to the B-cell non-Hodgkin lymphoma market?
What is the structure of clinical trial landscape by status related to the B-cell non-Hodgkin lymphoma market?
What is the structure of clinical trial landscape by phase related to the B-cell non-Hodgkin lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the B-cell non-Hodgkin lymphoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 B-CELL NON-HODGKIN LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 B-CELL NON-HODGKIN LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 B-CELL NON-HODGKIN LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 B-CELL NON-HODGKIN LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 B-CELL NON-HODGKIN LYMPHOMA - UNMET NEEDS
10 B-CELL NON-HODGKIN LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 B-CELL NON-HODGKIN LYMPHOMA - MARKETED PRODUCTS
11.1 List of B-Cell Non-Hodgkin Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Zydelig (Idelalisib) - Gilead Sciences
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Treanda (Bendamustine) - Astellas Pharma GmbH
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Rituxan (Rituximab) - Biogen Idec/Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 B-CELL NON-HODGKIN LYMPHOMA - PIPELINE DRUGS
12.1 List of B-Cell Non-Hodgkin Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Odronextamab - Regeneron Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 UCART20x22 - Cellectis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BI-1206 - BioInvent International AB
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Loncastuximab tesirine - ADC Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Glofitamab - Roche
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. B-CELL NON-HODGKIN LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. B-CELL NON-HODGKIN LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 B-CELL NON-HODGKIN LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
16 B-CELL NON-HODGKIN LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 B-CELL NON-HODGKIN LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 B-CELL NON-HODGKIN LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 B-CELL NON-HODGKIN LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 B-CELL NON-HODGKIN LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 B-CELL NON-HODGKIN LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 B-CELL NON-HODGKIN LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 B-CELL NON-HODGKIN LYMPHOMA - UNMET NEEDS
10 B-CELL NON-HODGKIN LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 B-CELL NON-HODGKIN LYMPHOMA - MARKETED PRODUCTS
11.1 List of B-Cell Non-Hodgkin Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Zydelig (Idelalisib) - Gilead Sciences
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Treanda (Bendamustine) - Astellas Pharma GmbH
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Rituxan (Rituximab) - Biogen Idec/Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 B-CELL NON-HODGKIN LYMPHOMA - PIPELINE DRUGS
12.1 List of B-Cell Non-Hodgkin Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Odronextamab - Regeneron Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 UCART20x22 - Cellectis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BI-1206 - BioInvent International AB
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Loncastuximab tesirine - ADC Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Glofitamab - Roche
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. B-CELL NON-HODGKIN LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. B-CELL NON-HODGKIN LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 B-CELL NON-HODGKIN LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 B-Cell Non-Hodgkin Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 B-Cell Non-Hodgkin Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 B-Cell Non-Hodgkin Lymphoma - Access and Reimbursement Overview
16 B-CELL NON-HODGKIN LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 B-CELL NON-HODGKIN LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 B-CELL NON-HODGKIN LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
